Sort   by:  
 Page size 
MetabolomicsMetabolic responses to PD1 immune-checkpoint blockade and association with therapeutic benefits - Part III
Not available
ORGANISM(S): Homo sapiens 
ST001237 | MetabolomicsWorkbench
MetabolomicsMetabolic responses to PD1 immune-checkpoint blockade and association with therapeutic benefits - Part II
Not available
ORGANISM(S): Homo sapiens 
ST001236 | MetabolomicsWorkbench
MetabolomicsMetabolic responses to PD1 immune-checkpoint blockade and association with therapeutic benefits - Part I
Not available
ORGANISM(S): Homo sapiens 
ST001235 | MetabolomicsWorkbench
ProteomicsMapping of immunopeptidome of cancer immunotherapy with oncolytic virus and checkpoint blockade
The elucidation of therapy-induced changes to the class I major histocompatibility complex (MHC-I)-bound tumor antigens is crucial for understanding immune-mediated tumor eradication and identifying potential targets for peptide vaccines to enhance the efficacy of immunotherapies. Here, we investiga...
ORGANISM(S): Mus musculus (Mouse) 
2021-12-06 | PXD024369 | Pride
Antitumor immunity Mhc immunoprecipitation Immune checkpoint blockade Oncolytic virus Lc-sps-ms3 Murine Fibrosarcoma Lc-ms/ms 
TranscriptomicsCheckpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor infiltrating CD8+ T cells
Coinhibitory receptor blockade is a promising strategy to boost immunity against a variety of human cancers. However, many patients still do not benefit from this treatment, and responders often experience immune-related toxicities. These issues highlight the need for improved understanding of check...
ORGANISM(S): Mus musculus 
2014-12-18 | E-GEOD-58722 | biostudies-arrayexpress
ProteomicsAntibody-lectin chimeras for glyco-immune checkpoint blockade
Despite the curative potential of checkpoint blockade immunotherapy, most patients remain unresponsive to existing treatments. Glyco-immune checkpoints – interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors – have emerged as prominent mechanisms of immune evasion and ...
ORGANISM(S): Homo sapiens (Human) 
2025-08-13 | PXD063934 | Pride
Antibody-lectin chimeras for glyco-immune checkpoint blockade 
ProteomicsSerum proteome profiling of patients with non-small cell lung cancer treated with immune checkpoint blockade monotherapy
Shotgun proteomic profiling of serum from patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint blockade (ICB) monotherapy. Top-14 abundant proteins were depleted (Pierce High-Select, Thermo Fisher Scientific), and tryptic digests were spiked with the Pierce Peptide Retenti...
ORGANISM(S): Homo Sapiens (human) 
2026-06-10 | PXD078247 | JPOST Repository
GenomicsSingle Cell Transcriptomics of peripheral immune cells pre- and post-Immune Checkpoint Blockade
Raw sequencing data for magnetically-sorted CD8+ T cells and monocytes from the peripheral blood of eight individuals receiving immune checkpoint blockade (either combination ipilimumab/nivolumab, n=4; or single-agent pembrolizumab, n=4) for the treatment of metastatic melanoma. Samples were taken i...
EGAS00001005507 | EGA
GenomicsA Multifactorial Tumor and Immune Cell Profile Determines Response to Immune Checkpoint blockade in Melanoma
The complex crosstalk between tumor and immune cells during immune checkpoint blockade mandates the development of integrated models that interpret the anti-tumor immune response and predict clinical outcome. We have integrated genome-wide sequence and structural alterations with pre and on-therapy ...
EGAS00001004548 | EGA
ProteomicsInhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance
Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies due to the functional impairment of effector T cells and their inefficient trafficking to tumours. T-cell activation is negatively regulated by C-terminal Src kinase (CSK); however, the exact mechanism remains unknown....
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037546 | Pride
Phosphotyrosine Immune checkpoint blockade Ack1 Prostate cancer Src 
Sort   by:  
 Page size